目的 探讨桉柠蒎肠溶软胶囊联合布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法 选取2024年1月—2026年1月驻马店市中心医院收治的82例慢性阻塞性肺疾病急性加重期患者为研究对象，采用简单随机数字表法分为对照组和治疗组，每组41例。对照组给予布地格福吸入气雾剂，2揿/次，2次/d。治疗组在对照组治疗基础上口服桉柠蒎肠溶软胶囊，1粒/次，3次/d。两组均连续治疗2周。比较两组的总有效率、临床症状量表评分、肺功能指标、气道黏液分泌指标、炎性反应指标。结果 治疗组的总有效率95.12%显著高于对照组的80.49%（P＜0.05）。治疗后两组改良版英国医学研究委员会呼吸问卷（mMRC）、咳嗽和咳痰评估问卷（CASA-Q）评分较治疗前均明显降低（P＜0.05），且治疗组mMRC、CASA-Q评分明显低于对照组（P＜0.05）。治疗后两组用力肺活量（FVC）、呼气高峰流量（PEF）、第一秒用力呼气量（FEV1）、FEV1占预计值百分比（FEV1pre%）、FEV1/FVC较治疗前均显著升高（P＜0.05），且治疗组FVC、PEF、FEV1、FEV1pre%、FEV1/FVC明显高于对照组（P＜0.05）。治疗后两组杯状细胞黏液蛋白（MUC5AC）、中性粒细胞弹力蛋白酶（NE）均显著下降（P＜0.05），且治疗组MUC5AC、NE低于对照组（P＜0.05）。治疗后两组超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）、血清淀粉样蛋白A（SAA）、可溶性髓样细胞触发受体-1（sTREM-1）均显著降低（P＜0.05），且治疗组hs-CRP、IL-6、SAA、sTREM-1低于对照组（P＜0.05）。结论 桉柠蒎肠溶软胶囊联合布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期的临床疗效确切，可有效改善患者呼吸困难、咳嗽咳痰症状，提升肺功能，减轻气道黏液高分泌状态和全身炎性反应。

Objective To investigate the clinical efficacy of Eucalyptol, Limonene and Pinene Enteric Soft Capsules combined with Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 82 patients with AECOPD admitted to Zhumadian Central Hospital from January 2024 to January 2026 were selected as the study subjects. They were divided into control group and treatment group using a simple random number table method, with 41 cases in each group. The control group received Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol 2 puffs per dose, twice daily. The treatment group was administered Eucalyptol, Limonene and Pinene Enteric Soft Capsules on top of the control group's regimen, 1 capsule per dose, three times daily. Two groups were treated continuously for 2 weeks. The total effective rate, clinical symptom scale scores, pulmonary function indicators, airway mucus secretion indicators, and inflammatory response indicators were compared between two groups. Results The total effective rate of the treatment group was 95.12%, significantly higher than the control group's 80.49% (P < 0.05). After treatment, the scores of the modified version of the British Medical Research Council Respiratory Questionnaire (mMRC) and Cough and Phlegm Assessment Questionnaire (CASA-Q) in two groups were significantly reduced (P < 0.05), and the mMRC and CASA-Q scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the forced vital capacity (FVC), peak expiratory flow (PEF), forced expiratory volume in one second (FEV1), percentage of FEV1 to predicted value (FEV1pre%), and FEV1/FVC of two groups significantly increased (P < 0.05). Furthermore, FVC, PEF, FEV1, FEV1pre%, and FEV1/FVC ratio in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of goblet cell mucin protein (MUC5AC) and neutrophil elastase (NE) in two groups significantly decreased (P < 0.05), and the levels of MUC5AC and NE in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), serum amyloid A (SAA), and soluble myeloid trigger receptor-1 (sTREM-1) were significantly reduced in two groups (P < 0.05), and hs-CRP, IL-6, SAA, and sTREM-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion The clinical efficacy of the combination of Eucalyptol, Limonene and Pinene Enteric Soft Capsules and Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol is definite in treatment of acute exacerbation of chronic obstructive pulmonary disease. It can effectively improve patients' breathing difficulties, cough and sputum symptoms, enhance lung function, alleviate airway mucus hypersecretion and systemic inflammatory reactions.

R974

河南省科技发展计划（222102310510）